DrugPatentWatch Database Preview
Patent: 10,095,829
Summary for Patent: 10,095,829
| Title: | Computer implemented methods of treating lung cancer |
| Abstract: | The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumor in an individual comprising the molecular characterization of the tumor, and the calculation of a score for the plurality of drugs essentially based on the percentage of deregulated target genes. |
| Inventor(s): | Lazar; Vladimir (Villejuif, FR), Soria; Jean-Charles (Igny, FR), Ducreux; Michel (Vanves, FR), Tursz; Thomas (Paris, FR) |
| Assignee: | WORLDWIDE INNOVATIVE NETWORK (Villejuif, FR) |
| Application Number: | 13/382,585 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,095,829
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | ⤷ Free Forever Trial | WORLDWIDE INNOVATIVE NETWORK (Villejuif, FR) | 2029-07-08 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | ⤷ Free Forever Trial | WORLDWIDE INNOVATIVE NETWORK (Villejuif, FR) | 2029-07-08 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | ⤷ Free Forever Trial | WORLDWIDE INNOVATIVE NETWORK (Villejuif, FR) | 2029-07-08 | RX | search | |
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | ⤷ Free Forever Trial | WORLDWIDE INNOVATIVE NETWORK (Villejuif, FR) | 2029-07-08 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
